167 related articles for article (PubMed ID: 15928832)
1. Model of a specific human histamine H3 receptor (hH3R) binding pocket suitable for virtual drug design.
Schlegel B; Stark H; Sippl W; Höltje HD
Inflamm Res; 2005 Apr; 54 Suppl 1():S50-1. PubMed ID: 15928832
[No Abstract] [Full Text] [Related]
2. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
Axe FU; Bembenek SD; Szalma S
J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444
[TBL] [Abstract][Full Text] [Related]
3. A new class of histamine H3 receptor antagonists derived from ligand based design.
Roche O; Rodríguez Sarmiento RM
Bioorg Med Chem Lett; 2007 Jul; 17(13):3670-5. PubMed ID: 17498953
[TBL] [Abstract][Full Text] [Related]
4. Acidic elements in histamine H(3) receptor antagonists.
Sander K; von Coburg Y; Camelin JC; Ligneau X; Rau O; Schubert-Zsilavecz M; Schwartz JC; Stark H
Bioorg Med Chem Lett; 2010 Mar; 20(5):1581-4. PubMed ID: 20138762
[TBL] [Abstract][Full Text] [Related]
5. Molecular modeling of histamine H3 receptor and QSAR studies on arylbenzofuran derived H3 antagonists.
Dastmalchi S; Hamzeh-Mivehroud M; Ghafourian T; Hamzeiy H
J Mol Graph Model; 2008 Jan; 26(5):834-44. PubMed ID: 17561422
[TBL] [Abstract][Full Text] [Related]
6. Determination of the binding mode and interacting amino-acids for dibasic H3 receptor antagonists.
Levoin N; Labeeuw O; Krief S; Calmels T; Poupardin-Olivier O; Berrebi-Bertrand I; Lecomte JM; Schwartz JC; Capet M
Bioorg Med Chem; 2013 Aug; 21(15):4526-9. PubMed ID: 23787288
[TBL] [Abstract][Full Text] [Related]
7. A qualitative model for the histamine H3 receptor explaining agonistic and antagonistic activity simultaneously.
de Esch IJ; Timmerman H; Menge WM; Nederkoorn PH
Arch Pharm (Weinheim); 2000 Aug; 333(8):254-60. PubMed ID: 11008375
[TBL] [Abstract][Full Text] [Related]
8. Benzylpiperidine variations on histamine H3 receptor ligands for improved drug-likeness.
Wingen K; Schwed JS; Isensee K; Weizel L; Zivković A; Odadzic D; Stark H
Bioorg Med Chem Lett; 2014 May; 24(10):2236-9. PubMed ID: 24745967
[TBL] [Abstract][Full Text] [Related]
9. Recent medicinal chemistry of the histamine H3 receptor.
Letavic MA; Barbier AJ; Dvorak CA; Carruthers NI
Prog Med Chem; 2006; 44():181-206. PubMed ID: 16697898
[No Abstract] [Full Text] [Related]
10. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.
Esbenshade TA; Fox GB; Cowart MD
Mol Interv; 2006 Apr; 6(2):77-88, 59. PubMed ID: 16565470
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of histamine H
Watanabe M; Kobayashi T; Ito Y; Fukuda H; Yamada S; Arisawa M; Shuto S
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3630-3633. PubMed ID: 30385161
[TBL] [Abstract][Full Text] [Related]
12. Non-imidazole histamine H3 ligands. Part III. New 4-n-propylpiperazines as non-imidazole histamine H3-antagonists.
Walczyński K; Zuiderveld OP; Timmerman H
Eur J Med Chem; 2005 Jan; 40(1):15-23. PubMed ID: 15642406
[TBL] [Abstract][Full Text] [Related]
13. Novel H3 receptor antagonists with improved pharmacokinetic profiles.
Santora VJ; Covel JA; Hayashi R; Hofilena BJ; Ibarra JB; Pulley MD; Weinhouse MI; Semple G; Ren A; Pereira G; Edwards JE; Suarez M; Frazer J; Thomsen W; Hauser E; Lorea J; Grottick AJ
Bioorg Med Chem Lett; 2008 Jul; 18(14):4133-6. PubMed ID: 18554904
[TBL] [Abstract][Full Text] [Related]
14. An investigation of the absolute configuration of the potent histamine H3 receptor antagonist GT-2331 using vibrational circular dichroism.
Minick DJ; Copley RC; Szewczyk JR; Rutkowske RD; Miller LA
Chirality; 2007 Sep; 19(9):731-40. PubMed ID: 17575572
[TBL] [Abstract][Full Text] [Related]
15. Identification of Histamine H
Frandsen IO; Boesgaard MW; Fidom K; Hauser AS; Isberg V; Bräuner-Osborne H; Wellendorph P; Gloriam DE
Sci Rep; 2017 Jul; 7(1):4829. PubMed ID: 28684785
[TBL] [Abstract][Full Text] [Related]
16. An 80-amino acid deletion in the third intracellular loop of a naturally occurring human histamine H3 isoform confers pharmacological differences and constitutive activity.
Bongers G; Krueger KM; Miller TR; Baranowski JL; Estvander BR; Witte DG; Strakhova MI; van Meer P; Bakker RA; Cowart MD; Hancock AA; Esbenshade TA; Leurs R
J Pharmacol Exp Ther; 2007 Dec; 323(3):888-98. PubMed ID: 17855474
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the binding distribution of agonist and antagonist ligands for histamine H3 receptors in pig brain by quantitative autoradiography.
Mezzomo K; Cumming P; Minuzzi L
Eur J Pharmacol; 2007 Jun; 564(1-3):75-9. PubMed ID: 17350614
[TBL] [Abstract][Full Text] [Related]
18. Histamine H
Lopes FB; Aranha CMSQ; Fernandes JPS
Chem Biol Drug Des; 2021 Aug; 98(2):212-225. PubMed ID: 33991182
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and three-dimensional quantitative structure-activity relationship analysis of H3 receptor antagonists containing a neutral heterocyclic polar group.
Rivara S; Mor M; Bordi F; Silva C; Zuliani V; Vacondio F; Morini G; Plazzi PV; Carrupt PA; Testa B
Drug Des Discov; 2003; 18(2-3):65-79. PubMed ID: 14675944
[TBL] [Abstract][Full Text] [Related]
20. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
Hancock AA
Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
